Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein (Resimmune®) in Subjects With Mycosis Fungoides: A Phase II Multi-center Randomized Clinical Trial

Trial Profile

Safety and Effectiveness of A-dmDT390-bisFv(UCHT1) Fusion Protein (Resimmune®) in Subjects With Mycosis Fungoides: A Phase II Multi-center Randomized Clinical Trial

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2016

At a glance

  • Drugs A-dmDT390-anti-CD3bisFv immunotoxin (Primary) ; Vorinostat
  • Indications Mycosis fungoides
  • Focus Therapeutic Use
  • Acronyms Resimmune
  • Sponsors Angimmune
  • Most Recent Events

    • 27 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top